BTAI
NASDAQ
US
BioXcel Therapeutics, Inc. - Common Stock
$1.21
▲ +$0.03
(+2.12%)
Vol 130K
1
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$35.0M
ROE
-309.0%
Margin
-9070.6%
D/E
1640.68
Beta
0.25
52W
$1–$9
Wall Street Consensus
11 analysts · Apr 20262
Strong Buy
7
Buy
1
Hold
1
Sell
0
Strong Sell
81.8%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 60.0%
Next Report
May 11, 2026
EPS Estimate: $-0.52
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.52 | — | — |
| Dec 2025 | $-0.77 | $-0.58 | +$0.19 |
| Sep 2025 | $-1.20 | $-2.18 | $-0.98 |
| Jun 2025 | $-1.89 | $-2.45 | $-0.56 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $366K | $168K | $120K | $98K | $256K |
| Net Income | — | -$10.9M | -$7.3M | -$19.2M | -$30.9M | -$12.5M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -309.0% | -309.0% | -309.0% | -309.0% | -309.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -15989.2% | -5869.8% | -5869.8% | -5869.8% | -9070.6% | -9070.6% |
| Gross Margin | 10.8% | -144.6% | -144.6% | -144.6% | -28.2% | -28.2% |
| D/E Ratio | — | 1640.68 | 1640.68 | 1640.68 | 1640.68 | 1640.68 |
| Current Ratio | 0.76 | 0.76 | 0.76 | 0.76 | 1.17 | 1.17 |
Key Ratios
ROA (TTM)
-185.0%
P/S (TTM)
46.53
P/B
7.8
EPS (TTM)
$-10.41
CF/Share
$-7.34
52W High
$9.26
52W Low
$1.17
$1.17
52-Week Range
$9.26
Financial Health
Free Cash Flow
-$14.2M
Net Debt
$81.2M
Cash
$28.4M
Total Debt
$109.7M
As of Dec 31, 2025
How does BTAI compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
BTAI valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
46.5
▲
262%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
7.8
▲
219%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
BTAI profitability vs Biotechnology peers
ROE
-309.0%
▼
359%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-9070.6%
▼
3063%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
-28.2%
▼
136%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-185.0%
▼
296%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
BTAI financial health vs Biotechnology peers
D/E ratio
1640.7
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
1.2
▼
74%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.3
▼
74%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
BTAI fundamentals radar
BTAI
Peer median
Industry
BTAI profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
BTAI vs peers: key metrics
Latest News
No related news yet